Smoking-associated gene expression alterations in nasal epithelium reveal immune impairment linked to lung cancer risk.
Journal
Genome medicine
ISSN: 1756-994X
Titre abrégé: Genome Med
Pays: England
ID NLM: 101475844
Informations de publication
Date de publication:
08 Apr 2024
08 Apr 2024
Historique:
received:
31
03
2023
accepted:
18
03
2024
medline:
9
4
2024
pubmed:
9
4
2024
entrez:
8
4
2024
Statut:
epublish
Résumé
Lung cancer is the leading cause of cancer-related death in the world. In contrast to many other cancers, a direct connection to modifiable lifestyle risk in the form of tobacco smoke has long been established. More than 50% of all smoking-related lung cancers occur in former smokers, 40% of which occur more than 15 years after smoking cessation. Despite extensive research, the molecular processes for persistent lung cancer risk remain unclear. We thus set out to examine whether risk stratification in the clinic and in the general population can be improved upon by the addition of genetic data and to explore the mechanisms of the persisting risk in former smokers. We analysed transcriptomic data from accessible airway tissues of 487 subjects, including healthy volunteers and clinic patients of different smoking statuses. We developed a computational model to assess smoking-associated gene expression changes and their reversibility after smoking is stopped, comparing healthy subjects to clinic patients with and without lung cancer. We find persistent smoking-associated immune alterations to be a hallmark of the clinic patients. Integrating previous GWAS data using a transcriptional network approach, we demonstrate that the same immune- and interferon-related pathways are strongly enriched for genes linked to known genetic risk factors, demonstrating a causal relationship between immune alteration and lung cancer risk. Finally, we used accessible airway transcriptomic data to derive a non-invasive lung cancer risk classifier. Our results provide initial evidence for germline-mediated personalized smoke injury response and risk in the general population, with potential implications for managing long-term lung cancer incidence and mortality.
Sections du résumé
BACKGROUND
BACKGROUND
Lung cancer is the leading cause of cancer-related death in the world. In contrast to many other cancers, a direct connection to modifiable lifestyle risk in the form of tobacco smoke has long been established. More than 50% of all smoking-related lung cancers occur in former smokers, 40% of which occur more than 15 years after smoking cessation. Despite extensive research, the molecular processes for persistent lung cancer risk remain unclear. We thus set out to examine whether risk stratification in the clinic and in the general population can be improved upon by the addition of genetic data and to explore the mechanisms of the persisting risk in former smokers.
METHODS
METHODS
We analysed transcriptomic data from accessible airway tissues of 487 subjects, including healthy volunteers and clinic patients of different smoking statuses. We developed a computational model to assess smoking-associated gene expression changes and their reversibility after smoking is stopped, comparing healthy subjects to clinic patients with and without lung cancer.
RESULTS
RESULTS
We find persistent smoking-associated immune alterations to be a hallmark of the clinic patients. Integrating previous GWAS data using a transcriptional network approach, we demonstrate that the same immune- and interferon-related pathways are strongly enriched for genes linked to known genetic risk factors, demonstrating a causal relationship between immune alteration and lung cancer risk. Finally, we used accessible airway transcriptomic data to derive a non-invasive lung cancer risk classifier.
CONCLUSIONS
CONCLUSIONS
Our results provide initial evidence for germline-mediated personalized smoke injury response and risk in the general population, with potential implications for managing long-term lung cancer incidence and mortality.
Identifiants
pubmed: 38589970
doi: 10.1186/s13073-024-01317-4
pii: 10.1186/s13073-024-01317-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
54Subventions
Organisme : Cancer Research UK
ID : C14303/A17197, A19274
Pays : United Kingdom
Informations de copyright
© 2024. The Author(s).
Références
GBD 2019 Tobacco Collaborators. Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990-2019: a systematic analysis from the Global Burden of Disease Study 2019. Lancet [Internet]. 2021; https://doi.org/10.1016/S0140-6736(21)01169-7 .
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30.
pubmed: 31912902
doi: 10.3322/caac.21590
Tindle HA, Stevenson Duncan M, Greevy RA, Vasan RS, Kundu S, Massion PP, et al. Lifetime Smoking History and Risk of Lung Cancer: Results From the Framingham Heart Study. J Natl Cancer Inst. 2018;110:1201–7.
pubmed: 29788259
pmcid: 6235683
National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395–409.
doi: 10.1056/NEJMoa1102873
de Koning HJ, van der Aalst CM, de Jong PA, Scholten ET, Nackaerts K, Heuvelmans MA, et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med. 2020;382:503–13.
pubmed: 31995683
doi: 10.1056/NEJMoa1911793
Field JK, Duffy SW, Baldwin DR, Whynes DK, Devaraj A, Brain KE, et al. UK Lung Cancer RCT Pilot Screening Trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening. Thorax. 2016;71:161–70.
pubmed: 26645413
doi: 10.1136/thoraxjnl-2015-207140
Hinde S, Crilly T, Balata H, Bartlett R, Crilly J, Barber P, et al. The cost-effectiveness of the Manchester “lung health checks”, a community-based lung cancer low-dose CT screening pilot. Lung Cancer. 2018;126:119–24.
pubmed: 30527175
doi: 10.1016/j.lungcan.2018.10.029
Spira A, Beane J, Shah V, Liu G, Schembri F, Yang X, et al. Effects of cigarette smoke on the human airway epithelial cell transcriptome. Proc Natl Acad Sci U S A. 2004;101:10143–8.
pubmed: 15210990
pmcid: 454179
doi: 10.1073/pnas.0401422101
Beane J, Sebastiani P, Liu G, Brody JS, Lenburg ME, Spira A. Reversible and permanent effects of tobacco smoke exposure on airway epithelial gene expression. Genome Biol. 2007;8:R201.
pubmed: 17894889
pmcid: 2375039
doi: 10.1186/gb-2007-8-9-r201
Spira A, Beane JE, Shah V, Steiling K, Liu G, Schembri F, et al. Airway epithelial gene expression in the diagnostic evaluation of smokers with suspect lung cancer. Nat Med. 2007;13:361–6.
pubmed: 17334370
doi: 10.1038/nm1556
Steiling K, Ryan J, Brody JS, Spira A. The field of tissue injury in the lung and airway. Cancer Prev Res. 2008;1:396–403.
doi: 10.1158/1940-6207.CAPR-08-0174
Gower AC, Steiling K, Brothers JF 2nd, Lenburg ME, Spira A. Transcriptomic studies of the airway field of injury associated with smoking-related lung disease. Proc Am Thorac Soc. 2011;8:173–9.
pubmed: 21543797
pmcid: 3159071
doi: 10.1513/pats.201011-066MS
Sridhar S, Schembri F, Zeskind J, Shah V, Gustafson AM, Steiling K, et al. Smoking-induced gene expression changes in the bronchial airway are reflected in nasal and buccal epithelium. BMC Genomics. 2008;9:259.
pubmed: 18513428
pmcid: 2435556
doi: 10.1186/1471-2164-9-259
Zhang X, Sebastiani P, Liu G, Schembri F, Zhang X, Dumas YM, et al. Similarities and differences between smoking-related gene expression in nasal and bronchial epithelium. Physiol Genomics. 2010;41:1–8.
pubmed: 19952278
doi: 10.1152/physiolgenomics.00167.2009
Silvestri GA, Vachani A, Whitney D, Elashoff M, Porta Smith K, Ferguson JS, et al. A bronchial genomic classifier for the diagnostic evaluation of lung cancer. N Engl J Med. 2015;373:243–51.
pubmed: 25981554
pmcid: 4838273
doi: 10.1056/NEJMoa1504601
AEGIS Study Team. Shared gene expression alterations in nasal and bronchial epithelium for lung cancer detection. J Natl Cancer Inst [Internet]. 2017:109. https://doi.org/10.1093/jnci/djw327 .
Beane JE, Mazzilli SA, Campbell JD, Duclos G, Krysan K, Moy C, et al. Molecular subtyping reveals immune alterations associated with progression of bronchial premalignant lesions. Nat Commun. 2019;10:1–13.
doi: 10.1038/s41467-019-09834-2
Pennycuick A, Teixeira VH, AbdulJabbar K, Raza SEA, Lund T, Akarca AU, et al. Immune surveillance in clinical regression of preinvasive squamous cell lung cancer. Cancer Discov. 2020;10:1489–99.
pubmed: 32690541
pmcid: 7611527
doi: 10.1158/2159-8290.CD-19-1366
Andrews S. FastQC - A quality control tool for high throughput sequence data [Internet]. Babraham Biopinformatics; 2010. Available from: http://www.bioinformatics.babraham.ac.uk/projects/fastqc/ . Accessed Mar 2023.
Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 2013;14:R36.
pubmed: 23618408
pmcid: 4053844
doi: 10.1186/gb-2013-14-4-r36
Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30:923–30.
pubmed: 24227677
doi: 10.1093/bioinformatics/btt656
Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.
pubmed: 25516281
pmcid: 4302049
doi: 10.1186/s13059-014-0550-8
Clyde MA, Ghosh J, Littman ML. Bayesian adaptive sampling for variable selection and model averaging. J Comput Graph Stat. 2011;20:80–101.
doi: 10.1198/jcgs.2010.09049
Friedman JH, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw. 2010;33:1–22.
pubmed: 20808728
pmcid: 2929880
doi: 10.18637/jss.v033.i01
Grau J, Grosse I, Keilwagen J. PRROC: computing and visualizing precision-recall and receiver operating characteristic curves in R. Bioinformatics. 2015;31:2595–7.
pubmed: 25810428
pmcid: 4514923
doi: 10.1093/bioinformatics/btv153
Yu G, Wang L-G, Han Y, He Q-Y. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16:284–7.
pubmed: 22455463
pmcid: 3339379
doi: 10.1089/omi.2011.0118
Loh P-R, Danecek P, Palamara PF, Fuchsberger C, Reshef YA, Finucane HK, et al. Reference-based phasing using the Haplotype Reference Consortium panel. Nat Genet. 2016;48:1443–8.
pubmed: 27694958
pmcid: 5096458
doi: 10.1038/ng.3679
Howie B, Fuchsberger C, Stephens M, Marchini J, Abecasis GR. Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. Nat Genet. 2012;44:955–9.
pubmed: 22820512
pmcid: 3696580
doi: 10.1038/ng.2354
Shabalin AA. Matrix eQTL: ultra fast eQTL analysis via large matrix operations. Bioinformatics. 2012;28:1353–8.
pubmed: 22492648
pmcid: 3348564
doi: 10.1093/bioinformatics/bts163
PCAWG Transcriptome Core Group, Calabrese C, Davidson NR, Demircioğlu D, Fonseca NA, He Y, et al. Genomic basis for RNA alterations in cancer. Nature. 2020;578:129–36.
doi: 10.1038/s41586-020-1970-0
Marigorta UM, Denson LA, Hyams JS, Mondal K, Prince J, Walters TD, et al. Transcriptional risk scores link GWAS to eQTLs and predict complications in Crohn’s disease. Nat Genet. 2017;49:1517–21.
pubmed: 28805827
pmcid: 5745037
doi: 10.1038/ng.3936
Buniello A, MacArthur JAL, Cerezo M, Harris LW, Hayhurst J, Malangone C, et al. The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. Nucleic Acids Res. 2019;47:D1005–12.
pubmed: 30445434
doi: 10.1093/nar/gky1120
Hunt SE, McLaren W, Gil L, Thormann A, Schuilenburg H, Sheppard D, et al. Ensembl variation resources. Database [Internet]. 2018;2018 https://doi.org/10.1093/database/bay119 .
Lachmann A, Giorgi FM, Lopez G, Califano A. ARACNe-AP: gene network reverse engineering through adaptive partitioning inference of mutual information. Bioinformatics. 2016;32:2233–5.
pubmed: 27153652
pmcid: 4937200
doi: 10.1093/bioinformatics/btw216
Ravasi T, Suzuki H, Cannistraci CV, Katayama S, Bajic VB, Tan K, et al. An atlas of combinatorial transcriptional regulation in mouse and man. Cell. 2010;140:744–52.
pubmed: 20211142
doi: 10.1016/j.cell.2010.01.044
Alvarez MJ, Shen Y, Giorgi FM, Lachmann A, Ding BB, Ye BH, et al. Functional characterization of somatic mutations in cancer using network-based inference of protein activity. Nat Genet. 2016;48:838–47.
pubmed: 27322546
pmcid: 5040167
doi: 10.1038/ng.3593
Vogelmeier CF, Criner GJ, Martínez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD Executive Summary. Arch Bronconeumol. 2017;53:128–49.
pubmed: 28274597
doi: 10.1016/j.arbres.2017.02.001
Smoking-dependent expression alterations in nasal epithelium reveal immune impairment linked to germline variation and lung cancer risk [Internet]. [cited 2024 Mar 4]. Available from: https://ega-archive.org/studies/EGAS00001006137 .
Merchant N, Nagaraju GP, Rajitha B, Lammata S, Jella KK, Buchwald ZS, et al. Matrix metalloproteinases: their functional role in lung cancer. Carcinogenesis. 2017;38:766–80.
pubmed: 28637319
doi: 10.1093/carcin/bgx063
Zhang C, Zhang G, Sun N, Zhang Z, Zhang Z, Luo Y, et al. Comprehensive molecular analyses of a TNF family-based signature with regard to prognosis, immune features, and biomarkers for immunotherapy in lung adenocarcinoma. EBioMedicine. 2020;59:102959.
pubmed: 32853987
pmcid: 7452643
doi: 10.1016/j.ebiom.2020.102959
Sullivan S, Tosetto M, Kevans D, Coss A, Wang L, O’Donoghue D, et al. Localization of nuclear cathepsin L and its association with disease progression and poor outcome in colorectal cancer. Int J Cancer. 2009;125:54–61.
pubmed: 19291794
doi: 10.1002/ijc.24275
Cortez MA, Masrorpour F, Ivan C, Zhang J, Younes AI, Lu Y, et al. Bone morphogenetic protein 7 promotes resistance to immunotherapy. Nat Commun. 2020;11:4840.
pubmed: 32973129
pmcid: 7519103
doi: 10.1038/s41467-020-18617-z
Chen Q, Tan KS, Liu J, Ong HH, Zhou S, Huang H, et al. Host antiviral response suppresses ciliogenesis and motile ciliary functions in the nasal epithelium. Front Cell Dev Biol. 2020;8:581340.
pubmed: 33409274
pmcid: 7779769
doi: 10.3389/fcell.2020.581340
Wu Z-H, Cai F, Zhong Y. Comprehensive Analysis of the Expression and Prognosis for GBPs in Head and neck squamous cell carcinoma. Sci Rep. 2020;10:6085.
pubmed: 32269280
pmcid: 7142114
doi: 10.1038/s41598-020-63246-7
Perez-Rogers JF, Gerrein J, Anderlind C, Liu G, Zhang S, Alekseyev Y, et al. Shared gene expression alterations in nasal and bronchial epithelium for lung cancer detection. J Natl Cancer Inst [Internet]. 2017;109 [cited 2021 Sep 15]. Available from: https://academic.oup.com/jnci/article-abstract/109/7/djw327/3053477 .
Okuda H, Kobayashi A, Xia B, Watabe M, Pai SK. Hyaluronan synthase HAS2 promotes tumor progression in bone by stimulating the interaction of breast cancer stem–like cells with macrophages and stromal cells. Cancer Res [Internet]. 2012; Available from: https://cancerres.aacrjournals.org/content/72/2/537.short .
Brichkina A, Bertero T, Loh HM, Nguyen NTM, Emelyanov A, Rigade S, et al. p38MAPK builds a hyaluronan cancer niche to drive lung tumorigenesis. Genes Dev. 2016;30:2623–36.
pubmed: 28007785
pmcid: 5204354
doi: 10.1101/gad.290346.116
Li M, Jin S, Cao Y, Xu J, Zhu S, Li Z. Emodin regulates cell cycle of non-small lung cancer (NSCLC) cells through hyaluronan synthase 2 (HA2)-HA-CD44/receptor for hyaluronic acid-mediated motility (RHAMM) interaction-dependent signaling pathway [Internet]. Cancer Cell Int. 2021; https://doi.org/10.1186/s12935-020-01711-z .
Feng Y, Ji D, Huang Y, Ji B, Zhang Y, Li J, et al. TGM3 functions as a tumor suppressor by repressing epithelial-to-mesenchymal transition and the PI3K/AKT signaling pathway in colorectal cancer. Oncol Rep. 2020;43:864–76.
pubmed: 32020212
pmcid: 7041123
Uemura N, Nakanishi Y, Kato H, Saito S, Nagino M, Hirohashi S, et al. Transglutaminase 3 as a prognostic biomarker in esophageal cancer revealed by proteomics [Internet]. Int J Cancer. 2009:2106–15. https://doi.org/10.1002/ijc.24194 .
Wu X, Cao W, Wang X, Zhang J, Lv Z, Qin X, et al. TGM3, a candidate tumor suppressor gene, contributes to human head and neck cancer. Mol Cancer. 2013;12:151.
pubmed: 24289313
pmcid: 4176127
doi: 10.1186/1476-4598-12-151
Hu J-W, Yang Z-F, Li J, Hu B, Luo C-B, Zhu K, et al. TGM3 promotes epithelial–mesenchymal transition and hepatocellular carcinogenesis and predicts poor prognosis for patients after curative resection. Dig Liver Dis. 2020;52:668–76.
pubmed: 31822388
doi: 10.1016/j.dld.2019.10.010
Mitselou A, Batistatou A, Nakanishi Y, Hirohashi S, Vougiouklakis T, Charalabopoulos K. Comparison of the dysadherin and E-cadherin expression in primary lung cancer and metastatic sites. Histol Histopathol. 2010;25:1257–67.
pubmed: 20712010
Tamura M, Ohta Y, Tsunezuka Y, Matsumoto I, Kawakami K, Oda M, et al. Prognostic significance of dysadherin expression in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg. 2005;130:740–5.
pubmed: 16153922
doi: 10.1016/j.jtcvs.2004.12.051
Lubarski GI. FXYD5: Na(+)/K(+)-ATPase regulator in health and disease. Front Cell Dev Biol. 2016;4:26.
Lubarski-Gotliv I, Asher C, Dada LA, Garty H. FXYD5 protein has a pro-inflammatory role in epithelial cells. J Biol Chem. 2016;291:11072–82.
pubmed: 27006401
pmcid: 4900257
doi: 10.1074/jbc.M115.699041
Honda K, Takaoka A, Taniguchi T. Type I inteferon gene induction by the interferon regulatory factor family of transcription factors. Immunity. 2006;25:349–60.
pubmed: 16979567
doi: 10.1016/j.immuni.2006.08.009
Steimle V, Siegrist CA, Mottet A, Lisowska-Grospierre B, Mach B. Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA. Science. 1994;265:106–9.
pubmed: 8016643
doi: 10.1126/science.8016643
Brass AL, Zhu AQ, Singh H. Assembly requirements of PU.1-Pip (IRF-4) activator complexes: inhibiting function in vivo using fused dimers. EMBO J. 1999;18:977–91.
pubmed: 10022840
pmcid: 1171190
doi: 10.1093/emboj/18.4.977
Froggatt HM, Harding AT, Chaparian RR, Heaton NS. ETV7 limits antiviral gene expression and control of influenza viruses. Sci Signal [Internet]. 2021:14. https://doi.org/10.1126/scisignal.abe1194 .
Kachuri L, Johansson M, Rashkin SR, Graff RE, Bossé Y, Manem V, et al. Immune-mediated genetic pathways resulting in pulmonary function impairment increase lung cancer susceptibility. Nat Commun. 2020;11:27.
pubmed: 31911640
pmcid: 6946810
doi: 10.1038/s41467-019-13855-2
Gourd E. New evidence that air pollution contributes substantially to lung cancer. Lancet Oncol. 2022;23:e448.
pubmed: 36116453
doi: 10.1016/S1470-2045(22)00569-1
Jorgovanovic D, Song M, Wang L, Zhang Y. Roles of IFN-γ in tumor progression and regression: a review. Biomark Res. 2020;8:49.
pubmed: 33005420
pmcid: 7526126
doi: 10.1186/s40364-020-00228-x
Altorki NK, Markowitz GJ, Gao D, Port JL, Saxena A, Stiles B, et al. The lung microenvironment: an important regulator of tumour growth and metastasis. Nat Rev Cancer. 2019;19:9–31.
pubmed: 30532012
pmcid: 6749995
doi: 10.1038/s41568-018-0081-9
Mascaux C, Angelova M, Vasaturo A, Beane J, Hijazi K, Anthoine G, et al. Immune evasion before tumour invasion in early lung squamous carcinogenesis. Nature. 2019;571:570–5.
pubmed: 31243362
doi: 10.1038/s41586-019-1330-0
De Biase S, Massip F, Schwarz RF. Smoking-associated gene expression alterations in nasal epithelium reveal immune impairment linked to lung cancer risk [Internet]. 2023. https://doi.org/10.5281/zenodo.10404844 .
doi: 10.5281/zenodo.10404844